593 related articles for article (PubMed ID: 20190639)
1. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
Feely MG; O'Dell JR
Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
[TBL] [Abstract][Full Text] [Related]
2. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
[TBL] [Abstract][Full Text] [Related]
4. Progression in early rheumatoid arthritis.
Combe B
Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):59-69. PubMed ID: 19233046
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies in early rheumatoid arthritis.
Smolen JS; Aletaha D; Machold KP
Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):163-77. PubMed ID: 15588977
[TBL] [Abstract][Full Text] [Related]
6. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
7. Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis.
Williams HJ
Br J Rheumatol; 1995 Nov; 34 Suppl 2():96-9. PubMed ID: 8535657
[TBL] [Abstract][Full Text] [Related]
8. Conventional disease-modifying antirheumatic drugs in early arthritis.
Sokka T; Hannonen P; Möttönen T
Rheum Dis Clin North Am; 2005 Nov; 31(4):729-44. PubMed ID: 16287594
[TBL] [Abstract][Full Text] [Related]
9. Early rheumatoid arthritis: strategies for prevention and management.
Combe B
Best Pract Res Clin Rheumatol; 2007 Feb; 21(1):27-42. PubMed ID: 17350542
[TBL] [Abstract][Full Text] [Related]
10. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
14. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
Kobayashi S; Kanai Y
Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
16. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
18. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
19. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
20. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
Osiri M; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
